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Pancreatic cancer patients with para-aortic lymph node metastasis have a poor prognosis and patients living longer
than 3 years are rare. We had a patient with pancreatic cancer who survived for more than 10 years after removal
of the para-aortic lymph node metastasis. A 57-year-old woman was diagnosed with pancreatic head cancer and
underwent a pancreaticoduodenectomy with subtotal gastric resection following Whipple reconstruction in 2000.
Para-aortic lymph node metastasis was detected during the operation by intraoperative pathological diagnosis and
an extended lymphadenectomy was performed with vascular skeletonization of the celiac and superior mesenteric
arteries. In 2004, a low-density area was detected around the superior mesenteric artery (SMA) 5 cm from its root
and she was treated with gemcitabine, and the area was undetectable after 3 years of treatment. In 2010,
computed tomography showed a low-density area around the same lesion with an increased carcinoembryonic
antigen level. After 4 months of gemcitabine treatment, we resected the tumor en bloc with the associated superior
mesenteric vein and perineural tissue. Histopathological examination of the resected specimen revealed a
well-differentiated tubular adenocarcinoma that closely resembled the original primary pancreatic cancer, indicating
perineural recurrence 10 years after the initial resection. She had no recurrence around the SMA for more than one
year. Although a meta-analysis has not proved the efficacy of preventive radical dissection, this case indicates that a
patient with well-differentiated, chemotherapy-responsive pancreatic cancer with para-aortic lymph node metastasis
could have a long survival time through extended dissection of the lymph nodes.
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Pancreatic cancer is among the leading causes of cancer
death in Japan and worldwide. Even with a curative resec-
tion, the overall 5-year survival rate is reported to be only
6.8% to 25% and the median survival time of resected
pancreatic cancer patients is 8 to 12 months [1-6]. For
pancreatic cancer, patients with metastasis to the para-
aortic lymph node have apparently shorter survival times
compared to patients without metastasis, implicating the
systemic spread of the tumors. Several previous reports
have indicated a median survival time (MST) of 5 to
12 months after resection in metastatic para-aortic
lymph node patients (Table 1). Most of these patients* Correspondence: tmasui@kuhp.kyoto-u.ac.jp
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reproduction in any medium, provided the orsurvived no more than 3 years. We report the case of a
patient who survived for more than 10 years after
pancreaticoduodenectomy for pancreatic cancer with
para-aortic lymph node metastasis. Moreover, during
follow-up a tumoral recurrence occurred 10 years later,
which was successfully resected.Case presentation
A 57-year-old woman with a history of jaundice was ad-
mitted to our hospital in October 2000, and an abdominal
computed tomography (CT) scan showed a low-density
mass of the pancreatic head (Figure 1a). No lymph node
metastasis was detected by preoperative CT or Ultrasound
Sonography (US).
No specific abdominal tumor was palpable by physical
examination. No superficial lymph nodes were palpable.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Median survival time of patients affected by pancreatic ductal adenocarcinoma with para-aortic lymph
node metastasis





(months) with PALN metastasis
Murakami et al. [7] 2009 103 17% 0% 12.4
Doi et al. [8] 2007 133 14% 0% 5.1
Shimada et al. [9] 2006 133 20% 0% 13
Sakai et al. [10] 2005 178 19% 3% NR
Yoshida et al. [11] 2004 34 26% 0% NR
Kayahara et al. [12] 1999 99 18% 11% NR
NR not reported; PALN para-aortic lymph node.
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Laboratory findings indicated slightly high levels of total
bilirubin and amylase. The levels of sialyl Lewis A
(CA19-9) and carcinoembryonic antigen (CEA) were
normal. In December 2000, we performed a pancrea-
ticoduodenectomy and a subtotal gastric resection. No as-
cites or peritoneal neoplastic dissemination were found.
The tumor was palpable at the pancreatic head. There was
no serosal invasion, but a retroperitoneal invasion was ob-
served. We performed an extended lymphadenectomy and
exeresis of the para-caval and para-aortic lymph nodes,
because of the intraoperative pathological diagnosis ofFigure 1 Primitive tumor CT imaging and histopathological findings.
low-density mass around the uncus of the pancreas (arrow). (b) Microscop
surrounded by an extracellular matrix (hematoxylin and eosin, ×40). (c) The
adenocarcinoma. (d) Resected perineural tissue with a histologic structuremetastasis to the para-aortic lymph nodes (Figure 1c). We
also performed a neural dissection around the root of
the SMA.
The size of the tumor was 2.8 × 2.0 × 2.0 cm. Histo-
pathological analysis revealed the tumor to be a well-
differentiated tubular adenocarcinoma (Figure 1b). The
tumor and the lymph node metastasis stained positive
for cytokeratin AE3/AE4, which implies an epithelial ori-
gin (data not shown). The tumor histologically showed
vascular, lymphatic and neural invasion and no cancer-
ous region was found at around the resection edge. Me-
tastasis was observed in lymph nodes 12b, 16b1 and(a) Computed tomography on admission showed a 22 mm× 25 mm
e analysis showed a well-differentiated tubular adenocarcinoma
para-aortic lymph node had a well-differentiated tubular
similar to the primitive tumor with hyalinization.
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International Union Against Cancer tumor-node-metas-
tasis classification was T3N1M1 (LYM) stage 4.
The postoperative course was uneventful and the patient
was discharged without postoperative chemotherapy be-
cause there was no standard adjuvant therapy at that time.
In 2004, CT examination revealed a low-density area
around the superior mesenteric artery (SMA) 5 cm from
its root, suggesting lymph node metastasis (Figure 2a). She
was treated with gemcitabine for 3 years. The tumor
disappeared gradually (Figure 2b). From 2007 to 2010,
there was no sign of recurrence even without chemother-
apy. In August 2010, a routine CT examination displayed
a low-density area around the SMA (Figure 2c) with a
CEA level above the reference range (13 U/ml). We
treated her with gemcitabine for 4 months, and no other
metastases were found. The tumor itself was within the
stable disease category (Figure 2d). In December 2010, we
resected the tumor around the SMA. There was no peri-
toneal dissemination or liver metastasis. The tumor was
tightly connected to the perineural tissue around the SMA
and had invaded the superior mesenteric vein (SMV)
(Figure 3a). However, it had not infiltrated the outer
membrane of the SMA. The tumor was resected en bloc
with the perineural tissue and the SMV, which was
reconstructed by end-to-end anastomosis (Figure 3b).
Histopathological examination of the resected specimenFigure 2 Low-density mass around SMA with chemotherapy. (a) CT ex
(b) The tumor disappeared gradually over 3 years (to 2007). (c) Routine CT
2010. (d) The tumor was within the stable disease range after 4 months of
SMA, which appeared after the first operation.revealed a well-differentiated tubular adenocarcinoma very
similar to the primitive pancreatic cancer (Figure 1d).
Hyalinized tissue surrounded the tumor, suggesting tumor
regression through chemotherapy. During the operation
the tumor looked like a lymph node metastasis according
to its CT localization. Histopathological examination
showed a pancreatic tumoral origin from the perineural
tissue of the SMA with invasion of the inner wall of the
SMV. The postoperative course was uneventful and
the patient recovered. An additional adjuvant treatment
with gemcitabine was given. The patient was recurrence
free for more than 1 year.Discussion
In patients with adenocarcinoma of the head of the pan-
creas, one of the factors predicting long-term survival is
the absence of metastatic lymph nodes [13,14]. Therefore,
to increase survival, extended lymphadenectomies have
been performed since the 1990s. However, this extended
procedure was not found to be beneficial for overall sur-
vival and seemed to be associated with increased morbid-
ity compared with the standard procedure [15].
Para-aortic lymph node metastasis has been observed
in around 14% to 26% of patients who underwent panc-
reaticoduodenectomy [7-12]. Thus far, there have been
six retrospective surveys on the survival of patients withamination revealed a low-density area around the SMA in 2004.
examination showed a low-density area around the SMA on August
gemcitabine treatment. Arrows show the low-density area around the
Figure 3 Intraoperative findings. (a) The tumor was tightly connected to the perineural tissue around the SMA with invasion of the SMV. (b) The
tumor was resected with the perineural tissue and the SMV. (c,d) illustration of (a) and (b). SMA, superior mesenteric artery; SMV, superior mesenteric vein.
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lymph node metastasis, and no patient survived longer
than 5 years (Table 1). However, our patient survived
for more than 10 years, although the tumor recurred in
the perineural tissue of the SMA. Several factors for
long survival times for pancreatic cancer patients have
been reported, including a low pre CA19-9 level, the nega-
tivity of the dissected margin of the tumor [16], tumor
differentiation [2,6,17] and the number of lymph node me-
tastases [14]. Massucco et al. claimed that not only the
number but also the localization of the metastases deter-
mines the prognosis [18]. In our case, we assume that the
long survival time is due to the characteristics of the
tumor and the extent of the operation: (1) the original
tumor was a well-differentiated adenocarcinoma, (2) it
showed good response to chemotherapy and (3) an ex-
tended lymphadenectomy was performed, which achived a
negative margin status.
Egawa et al. reported to the National Pancreatic
Cancer Registry that patients living longer than 5 years
after curative resection are those who have well-
differentiated primitive tumors, such as a papillarycarcinoma or a well-differentiated adenocarcinoma,
with good chemosensitivity [2,17]. Our patient had a well-
differentiated carcinoma and was treated with gemcitabine
for 3 years. The perineural recurrence around the SMA
almost completely vanished with this treatment. The
long survival time is apparently due to the good re-
sponse of the tumor to the gemcitabine treatment.
However, after a 2-year interval, the tumor recurred
again and showed no progression or regression on fur-
ther treatment with gemcitabine. Therefore, surgical
resection was deemed necessary. Recently Marechal et
al. reported that high activities of gemcitabine transport
and metabolism proteins are important for long survival
times after gemcitabine adjuvant therapy [19], su-
ggesting that a tumor that responds well to gemcitabine
treatment is genetically different from a non-responder.
Genetic alterations that affect a tumor’s response to
gemcitabine treatment should be analyzed when se-
lecting patients for extended lymphadenectomy.
Also, the extended lymphadenectomy seemed to be im-
portant for our patient. Indeed, we did not find any recur-
rent tumor around the aorta but in the perineural tissue
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cluded that the addition of extended lymphadenectomy
and retroperitoneal soft tissue clearance does not signifi-
cantly improve overall survival [15], surgical resection has
provided the only chance for long-term survival in pancre-
atic cancer patients, and exeresis of the metastatic lymph
node may be worthwhile for patients with chemotherapy-
responsive and well-differentiated pancreatic cancer de-
fined by ultrasound-guided fine needle aspiration cytology.
Recently, Kato et al. reported that initially unre-
sectable pancreatic cancer patients with a long-term fa-
vorable response to chemotherapy have long survival
times after adjuvant surgery [20]. They found 50% of
these patients survived for more than 5 years. Interest-
ingly, their analysis showed that distant metastasis, such
as peritoneal dissemination and liver metastasis rather
than local invasion, results in poor prognosis. But they
found only one case of metastasis in the para-aortic lymph
nodes. In our case, the tumor recurring around the SMA
had a good response to gemcitabine and was successfully
resected with at least 1 year of disease-free survival. There-
fore, neoadjuvant chemotherapy or adjuvant surgery could
be an effective choice for patients with local recurrence
even for pancreatic cancer.
Conclusions
In conclusion, we observed a case of pancreatic cancer
complicated by a para-aortic lymph node metastasis. After
an extended lymphadenectomy, the patient survived for
more than 10 years. According to our experience, for a
local tumoral recurrence treated by chemotherapy, a fur-
ther improvement in survival can be achieved by carefully
selecting patients to undergo adjuvant surgical treatment.
Consent
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for the publication of this report and any accompanying
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